menu
    • menu
    [{"orgOrder":0,"company":"Enesi Pharma Limited","sponsor":"Enesi Pharma Limited","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"AUSTRALIA","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"DNA Vaccine","moa":"Amyloid-beta-protein","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Enesi Pharma Limited","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enesi Pharma Limited \/ Enesi Pharma Limited","highestDevelopmentStatusID":"1","companyTruncated":"Enesi Pharma Limited \/ Enesi Pharma Limited"},{"orgOrder":0,"company":"Enesi Pharma Limited","sponsor":"Imperial College London","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"RNA Vaccine","moa":"SARS-CoV-2 S","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II","graph3":"Enesi Pharma Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enesi Pharma Limited \/ Enesi Pharma Limited","highestDevelopmentStatusID":"7","companyTruncated":"Enesi Pharma Limited \/ Enesi Pharma Limited"},{"orgOrder":0,"company":"Enesi Pharma Limited","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2021","type":"Agreement","leadProduct":"Influenza Vaccine Recombinant","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Enesi Pharma Limited","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Enesi Pharma Limited \/ National Institutes of Health","highestDevelopmentStatusID":"4","companyTruncated":"Enesi Pharma Limited \/ National Institutes of Health"},{"orgOrder":0,"company":"Enesi Pharma Limited","sponsor":"The Pirbright Institute","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Vaccine","year":"2020","type":"Inapplicable","leadProduct":"PRRSV vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Enesi Pharma Limited","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Enesi Pharma Limited \/ The Pirbright Institute","highestDevelopmentStatusID":"2","companyTruncated":"Enesi Pharma Limited \/ The Pirbright Institute"}]

    Find Clinical Drug Pipeline Developments & Deals by Enesi Pharma Limited

    Menu

    Enesi Pharma Limited

    EVENTS

    • Webinars & Exhibitions

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Enesi Pharma Limited

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Enesi Pharma Limited

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Influenza Vaccine Recombinant

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Enesi Pharma Enters Agreement with National Institutes of Health to Evaluate ImplaVax®-enabled Flu Vaccines

                            Details : ImplaVax®-enabled vaccination products leverage Enesi’s innovative unit solid-dose, thermally stable formulation and needle-free delivery technologies, and are applicable across all vaccine formats such as recombinant H7N9 pandemic influenza vaccine.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            October 19, 2021

                            Lead Product(s) : Influenza Vaccine Recombinant

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : National Institutes of Health

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Enesi Pharma Limited

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Enesi Pharma Limited

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I/ Phase II

                            Recipient : Imperial College London

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Enesi Pharma and Imperial College London Collaborate to Develop Thermostable RNA Vaccines for Covid-19

                            Details : The collaboration will investigate the potential of combining Enesi's ImplaVax® technology for the creation of thermostable, solid dose vaccines with RNA vaccines based on Imperial's self-amplifying RNA technology and novel Polyplex DNA/RNA stabilisatio...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 18, 2020

                            Lead Product(s) : RNA Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Imperial College London

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Enesi Pharma Limited

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Enesi Pharma Limited

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PRRSV vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : The Pirbright Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Enesi Pharma's ImplaVax®-Enabled Live Virus Vaccine Produces Neutralising Antibody and T-Cell Responses Equiv...

                            Details : Study investigating potential of solid-dose vaccine for porcine reproductive and respiratory syndrome virus (PRRSV) conducted in collaboration with The Pirbright Institute.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            September 29, 2020

                            Lead Product(s) : PRRSV vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : The Pirbright Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Enesi Pharma Limited

                            United Kingdom arrow
                            AAPS
                            Not Confirmed

                            Enesi Pharma Limited

                            United Kingdom arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DNA Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Recipient : University of Adelaide

                            Deal Size : $0.9 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Enesi Pharma to Develop Thermostable Solid Dose DNA Vaccine Targeting Zika Virus Under New Partnership with th...

                            Details : This project aims to employ Enesi’s ImplaVax® formulation expertise and platform to create a protective Zika virus DNA vaccine in a solid dose implant format for transcutaneous delivery via a needle-free device.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            September 03, 2020

                            Lead Product(s) : DNA Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Recipient : University of Adelaide

                            Deal Size : $0.9 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth